Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

  • Mateo, F
  • Arenas, E J
  • Aguilar, H
  • Serra-Musach, J
  • de Garibay, G Ruiz
  • Boni, J
  • Maicas, M
  • Du, S
  • Iorio, F
  • Herranz-Ors, C
  • Islam, A
  • Prado, X
  • Llorente, A
  • Petit, A
  • Vidal, A
  • Català, I
  • Soler, T
  • Venturas, G
  • Rojo-Sebastian, A
  • Serra, H
  • Cuadras, D
  • Blanco, I
  • Lozano, J
  • Canals, F
  • Sieuwerts, A M
  • de Weerd, V
  • Look, M P
  • Puertas, S
  • García, N
  • Perkins, A S
  • Bonifaci, N
  • Skowron, M
  • Gómez-Baldó, L
  • Hernández, V
  • Martínez-Aranda, A
  • Martínez-Iniesta, M
  • Serrat, X
  • Cerón, J
  • Brunet, J
  • Barretina, M P
  • Gil, M
  • Falo, C
  • Fernández, A
  • Morilla, I
  • Pernas, S
  • Plà, M J
  • Andreu, X
  • Seguí, M A
  • Ballester, R
  • Castellà, E
  • Nellist, M
  • Morales, S
  • Valls, J
  • Velasco, A
  • Matias-Guiu, X
  • Figueras, A
  • Sánchez-Mut, J V
  • Sánchez-Céspedes, M
  • Cordero, A
  • Gómez-Miragaya, J
  • Palomero, L
  • Gómez, A
  • Gajewski, T F
  • Cohen, E E W
  • Jesiotr, M
  • Bodnar, L
  • Quintela-Fandino, M
  • López-Bigas, N
  • Valdés-Mas, R
  • Puente, X S
  • Viñals, F
  • Casanovas, O
  • Graupera, M
  • Hernández-Losa, J
  • Ramón Y Cajal, S
  • García-Alonso, L
  • Saez-Rodriguez, J
  • Esteller, M
  • Sierra, A
  • Martín-Martín, N
  • Matheu, A
  • Carracedo, A
  • González-Suárez, E
  • Nanjundan, M
  • Cortés, J
  • Lázaro, C
  • Odero, M D
  • Martens, J W M
  • Moreno-Bueno, G
  • Barcellos-Hoff, M H
  • Villanueva, A
  • Gomis, R R
  • Pujana, M A
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Academic engagement and commercialisation: a review of the literature on university-industry relations

  • Perkmann, Markus
  • Tartari, V.
  • McKelvey, M.
  • Autio, E.
  • Broström, A.
  • Fini, R.
  • Geuna, A.
  • Grimaldi, R.
  • Hughes, A.
  • Krabel, S.
  • Kitson, M.
  • Llerena, Patrick
  • Lissoni, F.
  • Salter, A.
  • Sobrero, Maurizio
  • Deste Cukierman, Pablo
[EN] A considerable body of work highlights the relevance of collaborative research, contract research, consulting and informal relationships for university-industry knowledge transfer. We present a systematic review of research on academic scientists' involvement in these activities to which we refer as 'academic engagement'. Apart from extracting findings that are generalisable across studies, we ask how academic engagement differs from commercialisation, defined as intellectual property creation and academic entrepreneurship. We identify the individual, organisational and institutional antecedents and consequences of academic engagement, and then compare these findings with the antecedents and consequences of commercialisation. Apart from being more widely practiced, academic engagement is distinct from commercialisation in that it is closely aligned with traditional academic research activities, and pursued by academics to access resources supporting their research agendas. We conclude by identifying future research needs, opportunities for methodological improvement and policy interventions. (C) 2012 Elsevier B.V. All rights reserved., We acknowledge support from the DIME Network, funded by the 6th Framework Programme of the European Commission (CIT3-CT-2005-513396). Additional support was provided by IMIT (Institute of Management of Innovation and Technology), the Advanced Institute of Management Research (AIM) (RES-331-27-0063), the UK Innovation Research Centre (UKIRC, RES-598-28-0001), University of Gothenburg, Alma Graduate School/University of Bologna and ANR (ANR-06-APPR-003).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Spanish students and teachers&apos, preferences towards computer-based and paper-and-pencil tests at universities

  • De-Siqueira, J.M.|||0000-0002-4579-1147
  • Peris Fajarnes, Guillermo|||0000-0001-9215-9091
  • Magal-Royo, Teresa|||0000-0002-7640-6264
  • Gimenez, Fernando
[EN] This study was conducted to identify and analyze some significant features that influence students and teachers about computer-based tests (CBT) and paper-and-pencil tests (P&P) at the context of the PAULEX Project. In order to do that, a large experiment has been developed at the Universidad Politécnica de Valencia (Polytechnic University of Valencia), Spain, in which several students and professors have answered a validated questionnaire about their usage of technology, feelings and experiences. They also compared their preferences after doing two similar basic tests, CBT and P&P., Acknowledgements are due to the Spanish Ministry of Science and Innovation for funding the PAULEX Project, to all participants of this experiment for their generous collaboration and to the Camille Research Group sponsors for cooperating.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Is the ORBIT bleeding risk score superior to the HAS-BLED score in anticoagulated atrial fibrillation patients?

  • Esteve-Pastor, María Asunción
  • García-Fernández, Amaya
  • Macías, Manuel
  • Segorb, Francisco
  • Valdés, Mariano
  • Roldán, Vanessa
  • Muñiz, Javier
  • Badimón, Lina
  • Roldán Rabadán, Inmaculada
  • Bertomeu-Martínez, Vicente
  • Cequier, Ángel
  • Lip, Gregory Y.H.
  • Anguita, Manuel
  • Marín, Francisco
Multicenter study, [Abstract] Background: Several bleeding risk scores have been validated in patients with atrial fibrillation (AF). The ORBIT score has been recently proposed as a simple score with the best ability to predict major bleeding. The present study aimed to test the hypothesis that the ORBIT score was superior to the HAS-BLED score for predicting major bleeding and death in "real world" anticoagulated AF patients. Methods and results: We analyzed the predictive performance for bleeding and death of 406 AF patients who underwent 571 electrical cardioversion procedures and 1,276 patients with permanent/persistent AF from the FANTASIIA registry. In the cardioversion population, 21 patients had major bleeding events and 26 patients died. The predictive performance for major bleeding of HAS-BLED and ORBIT were not significantly different (c-statistics 0.77 (95% CI 0.66-0.88) and 0.82 (95% CI 0.77-0.93), respectively; P=0.080). For the FANTASIIA population, 46 patients had major bleeding events and 50 patients died. The predictive performances for major bleeding of HAS-BLED and ORBIT were not significantly different (c-statistics 0.63 (95% CI 0.56-0.71) and 0.70 (95% CI 0.62-0.77), respectively; P=0.116). For death, the predictive performances of HAS-BLED and ORBIT were not significantly different in both populations. The ORBIT score categorized most patients as "low risk". Conclusions: Despite the original claims in its derivation paper, the ORBIT score was not superior to HAS-BLED for predicting major bleeding and death in a "real world" oral anticoagulated AF population. (Circ J 2016; 80: 2102-2108)., The FANTASIIA registry was funded by an unconditional grant from Pfizer/Bristol-Myers-Squibb and by grants from the Instituto de Salud Carlos III (Madrid)-FEDER (RD12/0042/0068, RD12/0042/0010, RD12/0042/0069 and RD12/0042/0063). The authors are supported by RD12/0042/0049 (RETICS) from ISCIII and PI13/00513/FEDER from ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Urolithins, ellagitannin metabolites produced by colon microbiota, inhibit Quorum Sensing in Yersinia enterocolitica: Phenotypic response and associated molecular changes

  • Giménez-Bastida, J. A.
  • Truchado, Pilar
  • Larrosa, Mar
  • Espín de Gea, Juan Carlos
  • Tomás Barberán, Francisco
  • Allende, Ana
  • García-Conesa, María Teresa
The mammalian enteropathogen Yersinia enterocolitica produces two main N-acylhomoserine lactones (AHLs) involved in Quorum Sensing (QS)-mediated infection processes, such as virulence, biofilm maturation and motility. Ellagitannin (ET)-rich fruits exhibit anti-QS activity but in vivo effects against intestinal pathogens may be associated to the ETs gut microbiota derived metabolites, urolithin-A (Uro-A) and urolithin-B (Uro-B). In this work we show that urolithins, at concentrations achievable in the intestine through the diet, reduce the levels of N-hexanoyl-l-homoserine lactone (C6-HSL) and N-(3-oxo-hexanoyl)-l-homoserine lactone (3-oxo-C6-HSL) in Y. enterocolitica and inhibit QS-associated biofilm maturation and swimming motility. These inhibitory effects were not associated to downregulation of the expression of some of the genes involved in the synthesis of AHLs (yenI and yenR) or in motility (flhDC, fliA, fleB). Our results suggest that urolithins may exert antipathogenic effects in the gut against Y. enterocolitica and highlight the need to investigate the antipathogenic in vivo properties of plant derived metabolites., This work has been supported by the following projects: Consolider Ingenio 2010-Fun-C-Food CSD2007-0063, CICYT BFU2007-60576, Fundación Seneca de la Región de Murcia (Grupo de Excelencia GERM 06, 04486) and the European Community’s Seventh Framework Programme (FP7) (244956, project BEEDOC). J.A.G.-B. and M.L. are holders of a predoctoral JAE scholarship and JAE-DOC contract, respectively, from CSIC (Spain). P.T. is holder of a predoctoral scholarship from the Fundación Seneca de la Región de Murcia., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A citrus extract containing flavanones represses plasminogen activator inhibitor-1 (PAI-1) expression and regulates multiple inflammatory, tissue repair, and fibrosis genes in human colon fibroblasts

  • Giménez-Bastida, J. A.
  • Martínez-Florensa, Mario
  • Espín de Gea, Juan Carlos
  • Tomás Barberán, Francisco
  • García-Conesa, María Teresa
The consumption of flavonoid-rich Citrus extracts has been associated with multiple beneficial effects including anti-inflammatory properties, but the potential effects on the inflammatory responses in the gut have not been thoroughly investigated. We used microarrays to search for molecular changes induced in human colon fibroblasts in response to the exposure to a flavanone-rich bitter orange extract under physiologically representative conditions. Dietary nontoxic levels of the predigested extract induced moderate but significant changes in the expression of genes associated with tissue repair and inflammation. Among the top regulated genes, plasminogen activator inhibitor 1 (PAI-1) was downregulated, and the matrix metallopeptidase 12 (MMP-12) was upregulated (mRNA and protein levels). Both proteins are involved in extracellular matrix (ECM) remodeling and fibroblast migration. The extract also affected the fibroblast migration and reduced monocyte adhesion, but the response was different in unstimulated cells and in cells pretreated with TNF-alpha. Collectively, these results were indicative of a moderate activation of the colon fibroblast inflammation-related function after exposure to the extract. Further investigations are required to identify the in vivo role of this Citrus derived extract in the maintenance of the normal balance in the intestine and in the pathogenesis of inflammatory diseases., This work has been supported by Zoster S.A. (Murcia, Spain), and by the Projects 05556/PI/04 (Fundación Séneca, Murcia, Spain) and by CSD2007-00063 (Fun-C-Food; Consolider Ingenio 2010). J.A.G.B. has a JAE fellowship from the Spanish ‘Consejo Superior de Investigaciones Cinetíficas’ (CSIC), and M.M.F. had a short term contract from Zoster S.A., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Benchmarking of bioinformatics tools for the hybrid de novo assembly of human and non-human whole-genome sequencing data

  • Muñoz-Barrera, Adrián
  • Rubio-Rodríguez, Luis A.
  • Jáspez, David
  • Corrales, Almudena
  • Marcelino Rodríguez, Itahisa
  • Ortiz, Lourdes
  • Mendoza, Pablo
  • Lorenzo-Salazar, José M.
  • González-Montelongo, Rafaela
  • Flores, Carlos
Accurate and complete de novo genome assemblies enable variant identification and the discovery of novel genomic features and biological functions. However, de novo assemblies of large and complex genomes remain challenging. Long-read sequencing data, alone or combined with short-read data, facilitate genome assembly. However, the literature has limited comprehensive evaluations of software performance, especially for human genome assembly. We benchmarked 11 pipelines, including four long-read only assemblers and three hybrid assemblers, combined with four polishing schemes, using the HG002 human reference material sequenced with Oxford Nanopore Technologies and Illumina. The best-performing pipeline was validated with non-reference human and non-human routine laboratory samples. Software performance was assessed using QUAST, BUSCO, and Merqury metrics, alongside computational cost analyses. We found that Flye outperformed all assemblers, particularly with Ratatosk error-corrected long-reads. Polishing improved the assembly accuracy and continuity, with two rounds of Racon and Pilon yielding the best results. The assembly of data from validation samples showed comparable assembly metrics to those of the reference material. Based on the results, a complete optimal analysis pipeline for the assembly, polishing, and contig curation developed on Nextflow is provided to enable efficient parallelization and built-in dependency management to further advance the generation of high-quality and chromosome-level assemblies., We would like to thank the support from our colleagues from the Teide-HPC Supercomputing facility (http://teidehpc.iter.es/en), which was funded by INP-2011-0063-PCT-430000-ACT (INNPLANTA program) from the Spanish Ministry of Economy and Competitiveness. AMB, LARR and JMLS acknowledge the training support provided by the University of La Laguna., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, F.
  • Arenas, E. J.
  • Aguilar, H.
  • Serra-Musach, J.
  • Ruiz de Garibay, G.
  • Boni, J.
  • Maicas, M.
  • Du, S.
  • Lorio, F.
  • Herranz-Ors, C.
  • Islam, A.
  • Prado, X.
  • Llorente, A.
  • Petit, A.
  • Vidal, A.
  • Catalá, I.
  • Soler, T.
  • Venturas, G.
  • Rojo-Sebastian, A.
  • Serra, H.
  • Cuadras, D.
  • Blanco, I.
  • Lozano, J.
  • Canals, F.
  • Sieuwerts, A. M.
  • Weerd, V. de
  • Look, M. P.
  • Puertas, S.
  • García, N.
  • Perkins, A. S.
  • Bonifaci, N.
  • Skowron, M.
  • Gómez-Baldó, L.
  • Hernández, V.
  • Martínez-Aranda, A.
  • Martínez-Iniesta, M.
  • Serrat, X.
  • Cerón, Julián
  • Brunet, J.
  • Barretina, M. P.
  • Gil, M.
  • Falo, C.
  • Fernández, A.
  • Morilla, I.
  • Pernas, S.
  • Plà, M. J.
  • Andreu, X.
  • Seguí, M. A.
  • Ballester, R.
  • Castellà, E.
  • Nellist. M.
  • Morales, S.
  • Valls, J.
  • Velasco, A.
  • Matias-Guiu, X.
  • Figueras, A.
  • Sánchez-Mut, José Vicente
  • Sánchez-Céspedes, M.
  • Cordero, A.
  • Gómez-Miragaya, J.
  • Palomero, L.
  • Gómez, A.
  • Gajewski, T. F.
  • Cohen, E. E. W.
  • Jesiotr, M.
  • Bodnar, L.
  • Quintela-Fandino, M.
  • López-Bigas, N.
  • Valdés-Mas, R.
  • Puente, X. S.
  • Viñals, F.
  • Casanovas, O.
  • Graupera, M.
  • Hernández-Losa, L.
  • Ramón y Cajal, S.
  • García-Alonso, L.
  • Sáez-Rodríguez, J.
  • Esteller, M.
  • Sierra, A.
  • Martín-Martín, N.
  • Matheu, A.
  • Carracedo, A.
  • González-Suárez, E.
  • Nanjundan, M.
  • Cortés, J.
  • Lázaro, C.
  • Odero, M. D.
  • Martens, J. W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, M. H.
  • Villanueva, A.
  • Gomis, R. R.
  • Pujana, M. A.
13 páginas, 7 figuras, Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure., This study was supported by the following bodies and grants: the Scientific Foundation ‘Asociación Española Contra el Cáncer’ (AECC, Stable Coordinated Group, Hereditary Cancer); the BBVA Foundation; the Eugenio Rodríguez Pascual Foundation grant 2012; Generalitat de Catalunya AGAUR SGR 2012 grants 283, 290 and 312, and SGR 2014 grants 364, 530, and 535; Spanish Ministry of Health ISCIII FIS grants PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, and PI14/00336. ISCIII RTICC grants RD06/0020/1051, RD12/0036/0007, RD12/0036/0008 and RD12/0036/0063; Spanish Ministry of Science and Innovation, ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’, MINECO grants SAF2010- 20203 and SAF2013-46196; and the Telemaraton 2014 ‘Todos Somos Raros, Todos Somos Únicos’ grant P35. EJA was supported by ‘la Caixa’ PhD fellowship program, F Iorio was supported by a fellowship from the EMBL-EBI and the Wellcome Trust Sanger Institute Postdoctoral (ESPOD) program, and NL-B, ME and RRG were supported by ICREA., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Continuous intraocular pressure monitoring in patients with obstructive sleep apnea syndrome using a contact lens sensor

  • Carnero, E.
  • Bragard, J.
  • Urrestarazu, E.
  • Rivas, E.
  • Polo, V.
  • Larrosa, J.M.
  • Antón, V.
  • Peláez, A.
  • Moreno-Montañés, J.
Purpose To analyse nocturnal intraocular pressure (IOP) fluctuations in patients with obstructive sleep apnea syndrome (OSAS) using a contact lens sensor (CLS) and to identify associations between the OSAS parameters determined by polysomnographic study (PSG) and IOP changes. Method Prospective, observational study. Twenty participants suspected of having OSAS were recruited. During PSG study, IOP was monitored using a CLS placed in the eye of the patient. The patients were classified according to the apnea-hypopnea index (AHI) in two categories, severe (>30) or mild/moderate (<30) OSAS. We evaluated several parameters determined by the IOP curves, including nocturnal elevations (acrophase) and plateau times in acrophase (PTs) defined by mathematical and visual methods. Results The IOP curves exhibited a nocturnal acrophase followed by PTs of varying extents at which the IOP remained higher than daytime measurement with small variations. We found significant differences in the length of the PTs in patients with severe OSAS compared to those with mild/moderate disease (P = 0.032/P = 0.028). We found a positive correlation between PTs and OSAS severity measured by the total number of apneic events (r = 0.681/ 0.751 P = 0.004/0.001) and AHI (r = 0.674/0.710, P = 0.004/0.002). Respiratory-related arousal and oxygen saturation also were associated significantly with the IOP PT length. Conclusions Periods of nocturnal IOP elevation lasted longer in severe OSAS patients than those with mild/moderate OSAS and correlate with the severity of the disease. The length of the nocturnal PT is also associated to respiratory parameters altered in patients with OSAS.
Docta Complutense
Publication Artículo científico (JournalArticle)

Identification of Immunoglobulin Gene Rearrangement Biomarkers in Multiple Myeloma through cfDNA-Based Liquid Biopsy Using tchDNA-Seq

  • Buenache, Natalia
  • Sánchez de la Cruz, Andrea
  • Cuenca, Isabel
  • Gimenez Sanchez, Alicia
  • Moreno Sanz, Laura
  • Martínez López, Joaquín
  • Rosa Rosa, Juan Manuel
Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of pathogenic CD138+ plasma cells (PPCs) in bone marrow (BM). Recent years have seen a significant increase in the treatment options for MM; however, most patients who achieve complete the response ultimately relapse. The earlier detection of tumor-related clonal DNA would thus be very beneficial for patients with MM and would enable timely therapeutic interventions to improve outcomes. Liquid biopsy of “cell-free DNA” (cfDNA) as a minimally invasive approach might be more effective than BM aspiration not only for the diagnosis but also for the detection of early recurrence. Most studies thus far have addressed the comparative quantification of patient-specific biomarkers in cfDNA with PPCs and BM samples, which have shown good correlations. However, there are limitations to this approach, such as the difficulty in obtaining enough circulating free tumor DNA to achieve sufficient sensitivity for the assessment of minimal residual disease. Herein, we summarize current data on methodologies to characterize MM, and we present evidence that targeted capture hybridization DNA sequencing (tchDNA-Seq) can provide robust biomarkers in cfDNA, including immunoglobulin (IG) rearrangements. We also show that detection can be improved by prior purification of the cfDNA. Overall, liquid biopsies of cfDNA to monitor IG rearrangements have the potential to provide important diagnostic, prognostic, and predictive information in patients with MM.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A baseline metabolomic signature is associated with immunological CD4 + T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Mallol, Roger
  • López Dupla, Miguel
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • Alba, Verónica|||0000-0002-5925-9573
  • Blanco, Julià|||0000-0002-2225-0217
  • Cañellas, Nicolau
  • Rull, Anna|||0000-0002-8907-7754
  • Leal, Manuel
  • Correig, Xavier|||0000-0002-6902-3054
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Vidal, Francesc|||0000-0002-6692-6186
Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 + T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data

  • Gel, Bernat|||0000-0001-8878-349X
  • Serra, Eduard|||0000-0003-2895-9857
Abstract. Motivation: Data visualization is a crucial tool for data Exploration, analysis and interpretation. For the visualization of genomic data there lacks a tool to create customizable non-circular plots of whole genomes from any species. Results: We have developed karyoploteR, an R/Bioconductor package to create linear chromosomal representations of any genome with genomic annotations and experimental data plotted along them. Plot creation process is inspired in R base graphics, with a main function creating karyoplots with no data and multiple additional functions, including custom functions written by the end-user, adding data and other graphical elements. This approach allows the creation of highly customizable plots from arbitrary data with complete freedomon data positioning and representation. Availability and implementation: karyoploteR is released under Artistic-2.0 License. Source code and documentation are freely available through Bioconductor http://www.bioconductor.org/pack ages/karyoploteR) and at the examples and tutorial page at https://bernatgel.gitHub.io/karyoploter_ tutorial. Contact: bgel@igtp.cat.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

  • Robles, Eloy F.
  • Mena-Varas, Maria
  • Barrio, Laura
  • Merino-Cortes, Sara V.
  • Balogh, Péter
  • Du, Ming-Qing
  • Akasaka, Takashi
  • Parker, Anton
  • Roa, Sergio
  • Panizo, Carlos
  • Martin-Guerrero, Idoia
  • Siebert, Reiner
  • Segura, Victor
  • Agirre, Xabier|||0000-0002-6558-9560
  • Macri-Pellizeri, Laura
  • Aldaz, Beatriz
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Zhang, Shaowei
  • Moody, Sarah
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Tousseyn, Thomas
  • Broccardo, Cyril
  • Brousset, Pierre
  • Campos-Sanchez, Elena
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Sánchez García, Isidro
  • Fernandez-Luna, Jose Luis
  • Garcia-Muñoz, Ricardo
  • Pena, Esther
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • González, Marcos
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Climent Bataller, Joan|||0000-0002-8927-6614
  • Ferrandez, Antonio
  • Sagaert, Xavier
  • Melnick, Ari M.
  • Prosper, Felipe|||0000-0001-6115-8790
  • Oscier, David G.
  • Carrasco, Yolanda R.
  • Dyer, Martin J. S.
  • Martinez-Climent, Jose A.
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2 - 3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3 -deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas. The homeobox NKX2 family of transcriptional factors has been shown to regulate fundamental developmental processes. Here, the authors show that NKX2-3 is a bona fide oncogenic driver in marginal-zone B-cell lymphoma and that it promotes lymphomagenesis by shaping lymphocyte dynamics and promoting BCR signalling.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Villarroya, Joan
  • Cereijo, Rubén|||0000-0002-1108-230X
  • Torres, Ferran|||0000-0002-7355-7913
  • Campderrós, Laura
  • Gallego-Escuredo, José Miguel
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mur, Isabel|||0000-0001-7660-8483
  • Corbacho, Noemí
  • Vidal, Francesc|||0000-0002-6692-6186
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Girlat, Marta|||0000-0001-7968-4190
Objective: People living with HIV (PLWH) have an increased cardiovascular risk (CVR) owing to dyslipidemia, insulin resistance, metabolic syndrome, and HIV/combination antiretroviral therapy (cART)-associated lipodystrophy (HALS). Atherosclerosis and inflammation are related to growth differentiation factor-15 (GDF15). The relationship between metabolic disturbances, HALS, and CVR with GDF15 in PLWH is not known. Research design and methods: Circulating GDF15 levels in 152 PLWH (with HALS = 60, without HALS = 43, cART-naïve = 49) and 34 healthy controls were assessed in a cross-sectional study. Correlations with lipids, glucose homeostasis, fat distribution, and CVR were explored. Results: PLWH had increased circulating GDF15 levels relative to controls. The increase was the largest in cART-treated PLWH. Age, homeostatic model assessment of insulin resistance 1 (HOMA1-IR), HALS, dyslipidemia, C-reactive protein, and CVR estimated with the Framingham score correlated with GDF15 levels. The GDF15-Framingham correlation was lost after age adjustment. No correlation was found between GDF15 and the D:A:D Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) score estimated CVR. CVR independent predictors were patient group (naïve, HALS-, and HALS+) and cumulated protease inhibitor or nucleoside reverse transcriptase inhibitor exposure. Conclusions: PLWH, especially when cART-treated, has increased GDF15 levels-this increase is associated with dyslipidemia, insulin resistance, metabolic syndrome, HALS, and inflammation-related parameters. GDF15 is unassociated with CVR when age-adjusted.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Standardized comparison of cardiovascular risk factors prevalence in spanish women and men living with hiv and in the general population

  • Camps-Vilaró, Anna|||0000-0001-9644-8421
  • Pérez-Fernández, Silvia|||0000-0002-9756-0092
  • Subirana, Isaac|||0000-0003-1676-0197
  • Teira, R.
  • Estrada, Vicente|||0000-0002-7795-5986
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Degano, Irene R.|||0000-0003-1914-6934
  • Marrugat, Jaume|||0000-0003-3320-554X
People living with HIV (PLWH) have an increased risk of cardiovascular (CV) disease, likely due to a higher prevalence of CV risk factors. We compared the age-standardized prevalence and management of CV risk factors in PLWH to that of the general population in Spain. Blood pressure, lipid, glucose, and anthropometric profiles were cross-sectionally compared along with the treatment of hypertension, dyslipidemia, and diabetes in a general population cohort and a PLWH cohort. Prevalence rates were standardized by the direct method by 10-year age groups in European standard populations and stratified by gender. We included 47,593 individuals aged 35 to 74 years, 28,360 from the general population cohort and 19,233 from the PLWH cohort. Compared to the general population, PLWH had a higher concentration of triglycerides (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)

  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mur, Isabel|||0000-0001-7660-8483
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Vidal, Francesc|||0000-0002-6692-6186
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
Introduction: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients, A Report From the FANTASIIA Registry

  • Esteve-Pastor, María Asunción|||0000-0003-3104-3460
  • Ruiz-Ortiz, Martín|||0000-0002-1479-7044
  • Muñiz, Javier|||0000-0002-3087-2067
  • Roldán-Rabadán, Inmaculada|||0000-0003-1299-5298
  • Otero, Déborah
  • Cequier, Ángel|||0000-0002-3230-0011
  • Bertomeu-Martínez, Vicente|||0000-0002-3553-0963
  • Badimon, Lina|||0000-0002-9162-2459
  • Anguita-Sánchez, Manuel|||0000-0001-7875-7263
  • Lip, Gregory Y. H.|||0000-0002-7566-1626
  • Marín, Francisco|||0000-0001-7246-7708
Background: An integrated and holistic approach is increasingly advocated in patients with atrial fibrillation (AF), based on the "Atrial fibrillation Better Care (ABC) pathway: A, Avoid stroke with anticoagulation; B, better symptom management; C, cardiovascular and comorbidity risk management." The aim of this study was to examine the prevalence of adherence to each component of the ABC pathway and to analyze its impact on long-term prognosis in the "real-world" cohort of AF patients from the FANTASIIA registry. Methods: This prospective study included consecutive AF outpatients anticoagulated with direct oral anticoagulants (DOAC) or vitamin K antagonists (VKA) from June 2013 to October 2014. From the ABC pathway, adherence to the "A criterion" was defined by a time in the therapeutic range (TTR) ≥ 70% or correct dose with DOAC; "B criterion" adherence was defined by a European Heart Rhythm Association (EHRA) Symptom Scale I-II; and "C criterion" adherence was defined as optimized risk factors and comorbidity management. Baseline features and embolic events, severe bleeding, and all-cause and cardiovascular mortality rates up to 3 years of follow-up were analyzed, and a Cox multivariate analysis was performed to investigate the role of each component of the ABC pathway in predicting major events. Results: A total of 1,955 AF patients (age: 74.4 ± 9.4 years; 43.2% female patients) were included in this study: adherence to A criterion was observed in 920 (47.1%) patients; adherence to B criterion was observed in 1,791 (91.6%) patients; and adherence to C criterion was observed in 682 (34.8%) patients. Only 394 (20.2%) of the whole population had good control of AF according to the ABC pathway. After a median follow-up of 1,078 days (IQR: 766-1,113), adherence to A criterion was independently associated with reduced cardiovascular mortality [HR: 0.67, 95%CI (0.45-0.99); p = 0.048] compared with non-adherence. Adherence to the B criterion was independently associated with reduced stroke [HR: 0.28, 95%CI (0.14-0.59); p < 0.001], all-cause mortality [HR: 0.49, 95%CI (0.35-0.69); p < 0.001], cardiovascular mortality [HR: 0.39, 95%CI (0.25-0.62); p < 0.001], and major adverse cardiovascular events (MACE) [HR: 0.41, 95%CI (0.28-0.62); p < 0.001] compared with non-adherence. AF patients with C criterion adherence had a significantly lower risk of myocardial infarction [HR: 0.31, 95%CI (0.15-0.66); p < 0.001]. Fully adherent ABC patients had a significant reduction in MACE [HR: 0.64, 95%CI (0.42-0.99); p = 0.042]. Conclusion: In real-world anticoagulated AF patients from FANTASIIA registry, we observed a lack of adherence to integrated care management of AF following the ABC pathway. AF managed according to the ABC pathway was associated with a significant reduction in adverse outcomes during long follow-up, suggesting the benefit of a holistic and integrated approach to AF management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation, A Report From the FANTASIIA Registry

  • Bertomeu-González, Vicente|||0000-0001-5309-0562
  • Moreno-Arribas, José|||0000-0002-4070-6476
  • Esteve-Pastor, María Asunción|||0000-0003-3104-3460
  • Roldán-Rabadán, Inmaculada|||0000-0003-1299-5298
  • Muñiz, Javier|||0000-0002-3087-2067
  • Raña-Míguez, Paula
  • Ruiz-Ortiz, Martín|||0000-0002-1479-7044
  • Cequier, Ángel|||0000-0002-3230-0011
  • Bertomeu-Martínez, Vicente|||0000-0002-3553-0963
  • Badimon, Lina|||0000-0002-9162-2459
  • Anguita-Sánchez, Manuel|||0000-0001-7875-7263
  • Lip, Gregory Y. H.|||0000-0002-7566-1626
  • Marín, Francisco|||0000-0001-7246-7708
Obesity and atrial fibrillation (AF) frequently coexist and independently increase mortality. We sought to assess the association between obesity and adverse events in patients receiving oral anticoagulants for AF. Consecutive AF outpatients receiving anticoagulant agents (both vitamin K antagonists and direct oral anticoagulants) were recruited into the FANTASIIA (Atrial fibrillation: influence of the level and type of anticoagulation on the incidence of ischemic and hemorrhagic stroke) registry. This observational, multicenter, and prospective registry of AF patients analyzes the quality of anticoagulation, incidence of events, and differences between oral anticoagulant therapies. We analyzed baseline patient characteristics according to body mass index, normal: <25 kg/m, overweight: 25-30 kg/m, and obese: ≥30 kg/m), assessing all-cause mortality, stroke, major bleeding and major adverse cardiovascular events (a composite of ischemic stroke, myocardial infarction, and total mortality) at 3 years' follow-up. In this secondary prespecified substudy, the association of weight on prognosis was evaluated. We recruited 1956 patients (56% men, mean age 73.8±9.4 years): 358 (18.3%) had normal body mass index, 871 (44.5%) were overweight, and 727 (37.2%) were obese. Obese patients were younger (P<0.01) and had more comorbidities. Mean time in the therapeutic range was similar across body mass index categories (P=0.42). After a median follow-up of 1070 days, 255 patients died (13%), 45 had a stroke (2.3%), 146 a major bleeding episode (7.5%) and 168 a major adverse cardiovascular event (8.6%). Event rates were similar between groups for total mortality (P=0.29), stroke (P=0.90), major bleeding (P=0.31), and major adverse cardiovascular events (P=0.24). On multivariate Cox analysis, body mass index was not independently associated with all-cause mortality, cardiovascular mortality, stroke, major bleeding, or major adverse cardiovascular events. In this prospective cohort of patients anticoagulated for AF, obesity was highly prevalent and was associated with more comorbidities, but not with poor prognosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, Francesca|||0000-0002-2342-7010
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Aguilar, Helena
  • Serra-Musach, Jordi
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Boni, Jacopo|||0000-0003-2626-9393
  • Maicas, Miren|||0000-0003-1404-5552
  • Du, Shisuo
  • Iorio, Francesco|||0000-0001-7063-8913
  • Herranz-Ors, Carmen|||0000-0002-2866-0321
  • Islam, Abul
  • Prado, X.
  • Llorente, Alicia
  • Petit Montserrat, Anna|||0000-0002-9284-095X
  • Vidal, August|||0000-0001-5727-2099
  • Català, Isabel
  • Soler, Teresa
  • Venturas, G.
  • Rojo-Sebastian, Alejandro|||0000-0001-6439-3518
  • Serra, Helena
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Lozano, José
  • Canals, Francesc|||0000-0002-0650-1135
  • Sieuwerts, Anieta M.
  • De Weerd, Vanja
  • Look, Maxime P.
  • Puertas, Sara
  • García, Nadia
  • Perkins, Archibald S.
  • Bonifaci, Núria|||0000-0002-8193-6825
  • Skowron, Margaretha A.
  • Gómez-Baldó, Laia
  • Hernández, Vanessa
  • Martínez-Aranda, Antonio
  • Martínez-Iniesta, Maria|||0000-0001-6252-6671
  • Serrat Farran, Xènia|||0000-0001-7611-5400
  • Cerón, Julián|||0000-0003-4739-2243
  • Brunet, Joan|||0000-0003-1945-3512
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil, Mercedes|||0000-0002-7387-2139
  • Falo, Catalina|||0000-0002-5714-6823
  • Fernández, Adela
  • Morilla, Idoia
  • Pernas, Sonia|||0000-0002-1485-5080
  • Plà, Maria Jesus
  • Andreu, Xavier
  • Seguí Palmer, Miguel Ángel|||0000-0002-5103-6746
  • Ballester, Rosa|||0000-0002-7870-4185
  • Castellà Fernández, Eva
  • Nellist, Mark D.
  • Morales, Saleta
  • Valls, Joan|||0000-0002-4806-7568
  • Velasco Sánchez, Ana
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Figueras, Agnes
  • Sánchez-Mut, José Vicente|||0000-0002-9292-8521
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
  • Cordero Casanovas, Alex|||0000-0002-2224-7122
  • Gómez-Miragaya, Jorge|||0000-0003-1801-4681
  • Palomero, Luis|||0000-0002-9144-1017
  • Gomez-Caamaño, Antonio|||0000-0002-9773-4590
  • Gajewski, Thomas F.
  • Cohen, Ezra E. W.
  • Jesiotr, Marzena
  • Bodnar, Lubomir
  • Quintela-Fandino, Miguel|||0000-0003-1648-1964
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Valdés-Mas, Rafael
  • Puente, Xose S.|||0000-0001-9525-1483
  • Viñals, Francesc|||0000-0002-9918-6751
  • Casanovas, Oriol|||0000-0002-4298-3995
  • Graupera, Mariona|||0000-0003-4608-4185
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Garcia-Alonso, Luz|||0000-0002-7863-9619
  • Saez-Rodriguez, J.
  • Esteller, M.|||0000-0003-4490-6093
  • Sierra-Jimenez, Angels|||0000-0003-1023-3492
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Matheu Fernandez, Ander
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Nanjundan, Meera
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Odero, Maria D.|||0000-0002-8858-2054
  • Martens, John W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, Mary Helen
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells

  • Maicas, Miren
  • Vázquez Urio, Iria
  • Alis, Rafael
  • Marcotegui, Nerea
  • Urquiza, Leire
  • Cortés-Lavaud, Xabier
  • Cristóbal, Ion
  • García-Sánchez, María A.
  • Odero, María D.
Acceso cerrado a este documento. No se encuentra disponible para la consulta pública. Depositado en Academica-e para cumplir con los requisitos de evaluación y acreditación académica del autor/a (sexenios, acreditaciones, etc.)., Transcriptional activation of the EVI1 oncogene (3q26) leads to aggressive forms of human acute myeloid leukemia (AML). However, the mechanism of EVI1-mediated leukemogenesis has not been fully elucidated. Previously, by characterizing the EVI1 promoter, we have shown that RUNX1 and ELK1 directly regulate EVI1 transcription. Intriguingly, bioinformatic analysis of the EVI1 promoter region identified the presence of several EVI1 potential binding sites. Thus, we hypothesized that EVI1 could bind to these sites regulating its own transcription. In this study, we show that there is a functional interaction between EVI1 and its promoter, and that the different EVI1 isoforms (EVI1-145 kDa, EVI1-Δ324 and MDS1-EVI1) regulate the transcription of EVI1 transcripts through distinct promoter regions. Moreover, we determine that the EVI1-145 kDa isoform activates EVI1 transcription, whereas EVI1-Δ324 and MDS1-EVI1 act as repressors. Finally, we demonstrate that these EVI1 isoforms are involved in cell transformation; functional experiments show that EVI1-145 kDa prolongs the maintenance of hematopoietic stem and progenitor cells; conversely, MDS1-EVI1 repressed hematopoietic stem and progenitor colony replating capacity. We demonstrate for the first time that EVI1 acts as a regulator of its own expression, highlighting the complex regulation of EVI1, and open new directions to better understand the mechanisms of EVI1 overexpressing leukemias., We thank Dr. Wieser (Medizinische Universitaet Wien) for the plasmid pEFzeo-MDS1EVI1, and Isabel Moreno-Miralles for technical support and useful discussion. This work was supported by Ministerio Educación y Ciencia (AP2007-03879); Ministerio de Economía y Competitividad (PI14/02073), integrado en el Plan Estatal de I+D+I 2013–2016 y cofinanciado por el ISCIII-Subdirección General de Evaluación y Fomento de la investigación y el Fondo Europeo de Desarrollo Regional (FEDER); Departamento de Salud del Gobierno de Navarra (29/2015); and ISCIII-RTICC (RD12/0036/0063).